CD8A and chronic graft versus host disease: With the clinical success of Proleukin in chronic graft versus host disease (GVHD) [34,35], a therapy that expands both CD4+ and CD8+ Tregs may increase the number of patients that achieve a clinical benefit in this severe immune-based disease [36].